[Role of Genetics in Precision Medicine of Coronary Artery Disease]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2025 Feb 28

PMID 40019575

Authors

V Sanin

R S Schmieder

W Koenig

L Li

H Schunkert

Z Chen

Affiliations

Soon will be listed here.

Abstract

Coronary artery disease (CAD) develops multifactorially through an interplay of lifestyle, environmental and genetic factors. Smoking, hypertension, hyperlipidemia, obesity and diabetes mellitus are modifiable risk factors for CAD. In addition, both rare mutations and multiple frequently occurring genetic variants can cause CAD, whereby the heritability of CAD is ca. 50%. Genetic diagnostics enable the early identification of affected children and adults and, based on a greatly increased cardiovascular risk, initiation of preventive treatment. In recent years, genome-wide association studies have identified hundreds of significant variants that together greatly increase the risk of CAD. In the general population the many frequently occurring risk alleles in combination with modifiable risk factors result in a widespread genetic predisposition to CAD. Their relevance arises in the context of an integrative risk assessment, whereby the additional genetic risk can be calculated by polygenic risk scores (PRS), which provide a hazard ratio that can be multiplied with the clinically determined risk. This overview article discusses the diagnostic principles of rare and frequent genetic causes of CAD as well as their implications in the precision treatment of the disease.

References

Hegele R, Boren J, Ginsberg H, Arca M, Averna M, Binder C . Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2019; 8(1):50-67. DOI: 10.1016/S2213-8587(19)30264-5. View

Do R, Stitziel N, Won H, Jorgensen A, Duga S, Merlini P . Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2014; 518(7537):102-6. PMC: 4319990. DOI: 10.1038/nature13917. View

Tregouet D, Konig I, Erdmann J, Munteanu A, Braund P, Hall A . Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009; 41(3):283-5. DOI: 10.1038/ng.314. View

Hegele R, Ban M, Cao H, McIntyre A, Robinson J, Wang J . Targeted next-generation sequencing in monogenic dyslipidemias. Curr Opin Lipidol. 2015; 26(2):103-13. DOI: 10.1097/MOL.0000000000000163. View

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

Trinder M, Francis G, Brunham L . Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2020; 5(4):390-399. PMC: 7042820. DOI: 10.1001/jamacardio.2019.5954. View

Linsel-Nitschke P, Gotz A, Erdmann J, Braenne I, Braund P, Hengstenberg C . Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. PLoS One. 2008; 3(8):e2986. PMC: 2500189. DOI: 10.1371/journal.pone.0002986. View

Erdmann J, Stark K, Esslinger U, Rumpf P, Koesling D, De Wit C . Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013; 504(7480):432-6. DOI: 10.1038/nature12722. View

Dang T, Kessler T, Wobst J, Wierer M, Braenne I, Strom T . Identification of a Functional Variant at the Chromosome 4q27 Coronary Artery Disease Locus in an Extended Myocardial Infarction Family. Circulation. 2021; 144(8):662-665. DOI: 10.1161/CIRCULATIONAHA.120.052975. View

10.

Khera A, Won H, Peloso G, Lawson K, Bartz T, Deng X . Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016; 67(22):2578-89. PMC: 5405769. DOI: 10.1016/j.jacc.2016.03.520. View

11.

Braenne I, Kleinecke M, Reiz B, Graf E, Strom T, Wieland T . Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet. 2015; 24(2):191-7. PMC: 4717192. DOI: 10.1038/ejhg.2015.100. View

12.

. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. Lancet. 2023; 403(10421):55-66. DOI: 10.1016/S0140-6736(23)01842-1. View

13.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

14.

Watts G, Gidding S, Hegele R, Raal F, Sturm A, Jones L . International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023; 20(12):845-869. DOI: 10.1038/s41569-023-00892-0. View

15.

Bedlington N, Abifadel M, Beger B, Bourbon M, Bueno H, Ceska R . The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration. GMS Health Innov Technol. 2022; 16:Doc04. PMC: 9583732. DOI: 10.3205/hta000136. View

16.

Gidding S, Wiegman A, Groselj U, Freiberger T, Peretti N, Dharmayat K . Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022; 29(18):2301-2311. DOI: 10.1093/eurjpc/zwac200. View

17.

Sanin V, Schmieder R, Ates S, Schlieben L, Wiehler J, Sun R . Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health. 2022; 32(3):422-428. PMC: 9159326. DOI: 10.1093/eurpub/ckac007. View

18.

Braamskamp M, Langslet G, McCrindle B, Cassiman D, Francis G, Gagne C . Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017; 136(4):359-366. DOI: 10.1161/CIRCULATIONAHA.116.025158. View

19.

Kusters D, Wiegman A, Kastelein J, Hutten B . Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res. 2013; 114(2):307-10. DOI: 10.1161/CIRCRESAHA.114.301430. View

20.

Luirink I, Wiegman A, Kusters D, Hof M, Groothoff J, de Groot E . 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019; 381(16):1547-1556. DOI: 10.1056/NEJMoa1816454. View